Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations
Immunotherapy emerged as an additional therapeutic arm in the arsenal against cancer. This new approach is directed towards the host ’s immune system and tumor microenvironment as opposed to the intratumor target of chemotherapy agents. It had achieved unprecedented prolonged responses in a variety of tumors. Immune checkpoint inhibitors (ICI) were the first agents to get numerous histology agnostic tumor approvals, challenging the concept of “one drug-one tumor”. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 3, 2024 Category: Cancer & Oncology Authors: Layal Rached, Ariane Laparra, Madona Sakkal, Fran çois-Xavier Danlos, Fabrice Barlesi, Franck Carbonnel, Eleonora De Martin, Michel Ducreux, Caroline Even, Jerome Le Pavec, Jean-Marie Michot, Joana MRibeiro, Florian Scotte, Santiago Ponce Aix, Olivier La Source Type: research
Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma − Heading towards a promising change in treatment paradigm
In an era where conventional treatment for pancreatic ductal adenocarcinoma (PDAC) using surgery and chemotherapy-based adjuvant modalities are associated with limited efficacy, significant toxicity and drug resistance, a shift in treatment paradigms is warranted to meet this major unmet clinical need. PDAC represents the 3rd leading cause of cancer death with a current 5-year Overall Survival (OS) rate of 12 % highlighting the need for development of new treatment approaches [1]. Such patients often present with locally advanced or metastatic disease by virtue of anatomy involving superior mesenteric arteries and veins...
Source: Cancer Treatment Reviews - May 2, 2024 Category: Cancer & Oncology Authors: Umair Mahmood, Ewa Carrier, Khurum Khan Tags: Anti-tumour Treatment Source Type: research
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment
Blood vessels have a fundamental role in embryonic development, wound healing, and body growth by providing adequate amount of oxygen, nutrients, metabolites, chemical mediators etc. It also helps to transport metabolic wastes, maintains homeostasis, body temperature and pH [1]. The physiological phenomenon in which new blood vessels are formed from pre-existing vessels is known as angiogenesis. The process begins with the formation of elongated filopodial protrusions, known as 'tip cells', in response to angiogenic signals. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 30, 2024 Category: Cancer & Oncology Authors: Sushree Subhadra Acharya, Chanakya Nath Kundu Tags: Anti-tumour Treatment Source Type: research
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
Salivary toxicity is an exceptionally common side effect of PSMA-targeted radiopharmaceuticals. In VISION, a phase III registrational trial for [177Lu]Lu-PSMA-617, the observed rate of grade 1 or 2 dry mouth was 39 % [1]. In a post-hoc exposure-adjusted analysis accounting for longer safety observation time, the adjusted incidence of any grade dry mouth was remarkably high at 75.1 per 100 patient treatment-years (PTY) [2]. Similar results have been reported in other large trials of [177Lu]Lu-PSMA-617. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 29, 2024 Category: Cancer & Oncology Authors: Miguel Muniz, Charles L Loprinzi, Jacob J Orme, Regina M Koch, Ahmed M Mahmoud, Adam M Kase, Irbaz B Riaz, Jack R Andrews, Matthew P Thorpe, Geoffrey B Johnson, Ayse T Kendi, Eugene D Kwon, Jones T Nauseef, Alicia K Morgans, Oliver Sartor, Daniel S Childs Tags: General and Supportive Care Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 28, 2024 Category: Cancer & Oncology Source Type: research
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials
The average five-year survival of metastatic renal cell carcinoma (mRCC) is 71%. However, there is significant variability in patient prognosis. Immune checkpoint inhibitors (ICIs) have been introduced into the treatment landscape of mRCC. This meta-analysis aimed to estimate progression-free and overall survival probabilities and identify possible outcome predictors of mRCC patients treated with ICI combination as first-line treatment. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 27, 2024 Category: Cancer & Oncology Authors: Marcello Tucci, Marta Mandar à, Jacopo Giuliani, Emilia Durante, Consuelo Buttigliero, Fabio Turco, Erica Palesandro, Ilaria Campisi, Navdeep Singh, Marco Muraro, Fernando Munoz, Francesco Fiorica Tags: Systematic or Meta-analysis Studies Source Type: research
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives
Head and neck squamous cell carcinoma (HNSCC) constitute a diverse category of cancer sites, encompassing oral cavity, pharynx, larynx, nasal cavity, and paranasal sinuses [1].These malignancies represent a significant global health challenge, affecting countries at various levels of development. According to data from The Global Cancer Observatory (GLOBOCAN) in 2020, HNSCC ranked as the seventh most common cancer worldwide [2]. Projections for 2030 predict an alarming global rise, primarily driven by tumors associated with the human papillomavirus (HPV)[1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 26, 2024 Category: Cancer & Oncology Authors: Pablo Jim énez-Labaig, Antonio Rullan, Irene Braña, Alberto Hernando-Calvo, Victor Moreno, Bernard Doger, George Bitar, Derfel Ap Dafydd, Alan Melcher, Kevin J. Harrington Tags: Anti-tumour Treatment Source Type: research
Agnostic drug development revisited
The advent and rapid implementation of tissue-based or circulating tumor DNA next generation sequencing (NGS) in the clinic has enabled the identification of novel actionable genomic alterations present across tumor types[1]. Moreover, the number of agents approved that target specific actionable alterations has also increased enabling a shift in cancer treatment towards more personalized approaches paving the way for the implementation of precision oncology[2]. To date, a number of agents that target specific actionable alterations have shown superiority over standard-of-care cytotoxic agents and are part of the treatment...
Source: Cancer Treatment Reviews - April 26, 2024 Category: Cancer & Oncology Authors: Alberto Hernando-Calvo, Alice Rossi, Maria Vieito, Emile Voest, Elena Garralda Tags: New Drugs Source Type: research
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review
Gastric cancer (GC) is the sixth most commonly diagnosed cancer with a global incidence of more than one million cases and the fourth leading cause of cancer death with a mortality of 768.793 cases worldwide.[1] Five-year overall survival (OS) of patients with early GC is around 90 %, yet decreases to 50 % for stage II and III, and even less than 5 % for stage IV disease.[2] In case of metastatic disease, palliative systemic therapy can prolong life and is associated with a median OS of 11–14 months depending on the specific molecular profile. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 20, 2024 Category: Cancer & Oncology Authors: J. Bos, T.S. Groen-van Schooten, C.P. Brugman, F.S. Jamaludin, H.W.M. van Laarhoven, S. Derks Source Type: research
Dutch national guidelines for locally recurrent rectal cancer
After the introduction of total mesorectal excision (TME) and neoadjuvant treatment, the incidence of locally recurrent rectal cancer (LRRC) has decreased, but 6 –12 % of patients will still develop LRRC after primary rectal cancer.[1–5] At diagnosis, 40–60 % of patients present with distant metastases.[6–9] Detection of LRRC can be a challenge in itself, due to distorted anatomical planes and absence of the mesorectal fascia after primary rectal cancer surgery, the extra-luminal location of recurrences, and the presence of fibrosis or chronic inflammatory changes within the pelvis. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 18, 2024 Category: Cancer & Oncology Authors: Floor Piqeur, Davy M.J. Creemers, Evi Banken, Li ën Coolen, Pieter J. Tanis, Monique Maas, Mark Roef, Corrie A.M. Marijnen, Irene E.G. van Hellemond, Joost Nederend, Harm J.T. Rutten, Heike M.U. Peulen, Jacobus W.A. Burger Source Type: research
Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: A review of ongoing trials
The 5-year mortality rate for colon cancer (CC) patients is as high as 30 –50 % notwithstanding the implementation of screening programs leading to earlier diagnosis, the improvements in surgical techniques and the contribution of adjuvant therapy [1,2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 3, 2024 Category: Cancer & Oncology Authors: V. Conca, P. Cirac ì, C. Boccaccio, A. Minelli, C. Antoniotti, C. Cremolini Source Type: research
NTRK gene fusion testing and management in lung cancer
In non-small cell lung cancer (NSCLC), oncogene dysregulation due to activating mutations, fusions or amplifications is a frequent event. These recurring oncogenic alterations enable cancer cell survival and growth [1,2]. Lung cancers harbouring oncogenic drivers tend to rely on aberrant signalling for survival and growth, a concept known as ‘oncogene addiction’ [2,3]. This dependency on oncogene signalling, however, generates a unique vulnerability that can be exploited with the use of selective targeted agents such as tyrosine kinase inhibitors (TKIs) [2,4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 3, 2024 Category: Cancer & Oncology Authors: Matteo Repetto, Marina Chiara Garassino, Herbert H. Loong, Fernando Lopez-Rios, Tony Mok, Solange Peters, David Planchard, Sanjay Popat, Erin R. Rudzinski, Alexander Drilon, Caicun Zhou Tags: Anti-tumour Treatment Source Type: research
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group
Immunotherapy has revolutionized tumour treatment by harnessing the power of the immune system to fight cancer. Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab and tremelimumab), anti-programmed cell death protein 1 (PD-1) (nivolumab, pembrolizumab, cemiplimab, and dostarlimab), and anti-programmed death-ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab) monoclonal antibodies are among the most widely used immunotherapeutic agents for a variety of malignancies [1,2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 3, 2024 Category: Cancer & Oncology Authors: Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon Tags: Complications of Treatment Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 1, 2024 Category: Cancer & Oncology Source Type: research
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group
Angiosarcoma (AS) is a rare and aggressive vascular sarcoma. The current European Society of Medical Oncology (ESMO) clinical practice guidelines (CPGs) for the treatment of sarcomas apply to AS as well. However, AS aggressiveness and diverse tumor presentations differentiate it from other sarcomas, impacting clinical decisions. This is especially relevant in the context of localized disease, where considerations about the extent of surgery, the use of radiation therapy (RT), and the indication for neoadjuvant/adjuvant chemotherapy may vary. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 29, 2024 Category: Cancer & Oncology Authors: Elena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, Marta Barisella, Giuseppe Bianchi, Domenico Campanacci, Marco Fiore, Marco Gambarotti, Massimiliano Gennaro, Carlo Morosi, Federico Navarria, Emanuela Palmerini, Claudia Sangalli, Marta Sbaraglia, Annal Tags: REVIEW Source Type: research
